cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Taysha Gene Therapies Inc
11 own
8 watching
Current Price
$2.39
$-0.06
(-2.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
53.46M
52-Week High
52-Week High
3.89000
52-Week Low
52-Week Low
0.50000
Average Volume
Average Volume
0.27M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization53.46M
icon52-Week High3.89000
icon52-Week Low0.50000
iconAverage Volume0.27M
iconDividend Yield--
iconP/E Ratio--
What does the Taysha Gene Therapies Inc do?
Taysha Gene Therapies, Inc.is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we are advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs at no cost. Taysha Gene Therapies, Inc.principal executive offices are located at 2280 Inwood Road, Dallas, Texas 75235 and our telephone number is (214) 612-0000. Our website address is www.tayshagtx.com
Read More
How much money does Taysha Gene Therapies Inc make?
News & Events about Taysha Gene Therapies Inc.
Ticker Report
9 months ago
Taysha Gene Therapies, Inc. (NASDAQ:TSHA Get Rating) major shareholder R.A. Session II sold 295,653 shares of the companys stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $0.71, for a total value of $209,913.63. Following the transaction, the...
Zolmax
1 year ago
Taysha Gene Therapies (NASDAQ:TSHA Get Rating)s stock had its buy rating reaffirmed by investment analysts at Needham & Company LLC in a report released on Wednesday, Benzinga reports. They currently have a $6.00 price target on the stock. Several other equities research analysts have also recently ...
Zolmax
1 year ago
Taysha Gene Therapies (NASDAQ:TSHA Get Rating) had its price objective decreased by Truist Financial from $15.00 to $4.00 in a report released on Wednesday, The Fly reports. Truist Financial currently has a buy rating on the stock. Several other analysts have also weighed in on the company. ...
PR Newswire
1 year ago
Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? PR Newswire NEW YORK, Oct. 25, 2022 NEW YORK, Oct. 25, 2022...
Ticker Report
1 year ago
Taysha Gene Therapies (NASDAQ:TSHA Get Rating) had its price objective cut by research analysts at Chardan Capital from $34.00 to $32.00 in a research report issued on Friday, Marketbeat Ratings reports. The brokerage presently has a buy rating on the stock. Several other ...
Frequently Asked Questions
Frequently Asked Questions
What is Taysha Gene Therapies Inc share price today?
plus_minus_icon
Can Indians buy Taysha Gene Therapies Inc shares?
plus_minus_icon
How can I buy Taysha Gene Therapies Inc shares from India?
plus_minus_icon
Can Fractional shares of Taysha Gene Therapies Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Taysha Gene Therapies Inc stocks?
plus_minus_icon
What is today’s traded volume of Taysha Gene Therapies Inc?
plus_minus_icon
What is today’s market capitalisation of Taysha Gene Therapies Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Taysha Gene Therapies Inc?
plus_minus_icon
What percentage is Taysha Gene Therapies Inc down from its 52-Week High?
plus_minus_icon
What percentage is Taysha Gene Therapies Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.39
$-0.06
(-2.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.26
$0.05 (4.13 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$0.78
$-0.00 (-0.38 %)
Precision BioSciences Inc
Precision BioSciences Inc
$10.72
$-0.79 (-6.86 %)
ADC Therapeutics SA
ADC Therapeutics SA
$4.77
$-0.19 (-3.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.26
$0.05 (4.13 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$0.78
$-0.00 (-0.38 %)
Precision BioSciences Inc
Precision BioSciences Inc
$10.72
$-0.79 (-6.86 %)
ADC Therapeutics SA
ADC Therapeutics SA
$4.77
$-0.19 (-3.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00